Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Staff exchange2018–2023

NEOSETAC · New Selenium-based Targeted Nanocapsules to treat Breast Cancer

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2018-01-01 → 2023-10-31
EU contribution
€504,000
Participants
9
Scheme
MSCA-RISE

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Results in brief

New Selenium-based Targeted Nanocapsules to treat Breast Cancer

In the NEOSETAC project, breast cancer will be the focus of study being the most common cancers in women. It comprises of 10.4% of all the cancer incidences among women, causing 411.093 deaths per year all over the world. In Europe, there is more than twice of the amount of new breast cancer cases annually than new cases of cancer in any other place. Treatment for breast cancer is dependent on disease stage, histologic and molecular subtypes and menopausal status. Further aspects influencing treatment choice for early breast cancer include balancing the risk of relapse with the benefit of intervention and patient factors such as the impact of treatment on fertility. Surgery (mastectomy or breast-conserving surgery with or without lymph node dissection) and radiotherapy play an important role in early breast cancer: systemic therapy may be used for almost all women and is the predominant treatment for those with advanced disease The NEOSETAC project will demonstrate the anti-cancer therapeutic potential of a novel Selenium-based therapy for the management of breast cancer. A recent clinical study shows that high selenium exposure could decrease cancer risk, especially high plasma/serum selenium and toenail selenium. NEOSETAC will demonstrate the potential of a Selenium-based compounds cocktail to attack breast cancer cells; this compounds will be encapsulated in a targeted nanocapsule that will drive the compounds directly to the cancer cells. The overall research and development goal of the proposed action is twofold: to design and manufacture the Se-nanocapsules to treat breast cancer and demonstrate their therapeutic potential in pre-clinical studies.

Data: CORDIS, © European Union

Project objective

The European Chronic Diseases Alliance has defined cancer as one of the major non-communicable diseases, accountingfor 13% of the deaths worldwide, resulting in 8.2 million deaths annually. In the NEOSETAC project, breast cancer will be thefocus of study being the most common cancers in women. It comprises of 10.4% of all the cancer incidences among women,causing 411 093 deaths per year overall the world. In Europe, there is more than twice of the amount of new breast cancercases annually than new cases of cancer in any other place. The complexity of breast cancer makes it a big challenge forsuccessful treatment. The NEOSETAC project will demonstrate the anti-cancer therapeutic potential of a novel Seleniumbasedtherapy for the management of breast cancer. The clinical application of Selenium (Se) compounds for cancertreatment is until now limited in chemoprevention as dietary supplement. In this proposal, we aim to improve the therapeuticwindow, pharmacokinetic properties and targeting drug delivery via nanoparticles (NPs). By loading Se into biodegradableNPs, drug release is controlled within the narrow therapeutic window of Se. At the same time the uptake and activation of Secompounds at desired location (tumor lesions and metastasis) is achieved. We also propose to functionalize NPs by cancercell / cancer stem cell targeting ligands to further improve the therapeutic efficacy and prevent cancer recurrence afterchemotherapy. These advantages will lead to an enhanced anticancer activity and reduced systemic toxicity. Moreover,targeting via NPs will improve the pharmacokinetic properties and increase the relatively short half-life (~18 hours) of Se.

Original text from CORDIS.

Participants

  • UNIVERSITAT AUTONOMA DE BARCELONA · Cerdanyola Del VallesCoordinatorSpain
  • AB BCN SL · CERDANYOLA DEL VALLESSpain
  • ACIB GMBH · GrazAustria
  • ADSI-AUSTRIAN DRUG SCREENING INSTITUTE GMBH · InnsbruckAustria
  • CLINISCIENCES SL · BarcelonaSpain
  • KAROLINSKA INSTITUTET · STOCKHOLMSweden
  • QUALIZYME DIAGNOSTICS GMBH & CO KG · GrazCity levelAustria
  • REDINN - SRL · POMEZIAItaly
  • REGION STOCKHOLM · StockholmSweden

Links

Data: CORDIS, © European Union